| Style | Citing Format |
|---|---|
| MLA | Haghighat S, et al.. "Study and Comparison of the Effect of Tecar Therapy in the Symptoms and Functions of the Patients With Knee Osteoarthritis; a Non-Blind, Controlled Clinical Trial." Immunopathologia Persa, vol. 12, no. 2, 2026, pp. e43885-. |
| APA | Haghighat S, Yeganehfard P, Zare Dehnavi H, Dastanpour Hoseinabadi M (2026). Study and Comparison of the Effect of Tecar Therapy in the Symptoms and Functions of the Patients With Knee Osteoarthritis; a Non-Blind, Controlled Clinical Trial. Immunopathologia Persa, 12(2), e43885-. |
| Chicago | Haghighat S, Yeganehfard P, Zare Dehnavi H, Dastanpour Hoseinabadi M. "Study and Comparison of the Effect of Tecar Therapy in the Symptoms and Functions of the Patients With Knee Osteoarthritis; a Non-Blind, Controlled Clinical Trial." Immunopathologia Persa 12, no. 2 (2026): e43885-. |
| Harvard | Haghighat S et al. (2026) 'Study and Comparison of the Effect of Tecar Therapy in the Symptoms and Functions of the Patients With Knee Osteoarthritis; a Non-Blind, Controlled Clinical Trial', Immunopathologia Persa, 12(2), pp. e43885-. |
| Vancouver | Haghighat S, Yeganehfard P, Zare Dehnavi H, Dastanpour Hoseinabadi M. Study and Comparison of the Effect of Tecar Therapy in the Symptoms and Functions of the Patients With Knee Osteoarthritis; a Non-Blind, Controlled Clinical Trial. Immunopathologia Persa. 2026;12(2):e43885-. |
| BibTex | @article{ author = {Haghighat S and Yeganehfard P and Zare Dehnavi H and Dastanpour Hoseinabadi M}, title = {Study and Comparison of the Effect of Tecar Therapy in the Symptoms and Functions of the Patients With Knee Osteoarthritis; a Non-Blind, Controlled Clinical Trial}, journal = {Immunopathologia Persa}, volume = {12}, number = {2}, pages = {e43885-}, year = {2026} } |
| RIS | TY - JOUR AU - Haghighat S AU - Yeganehfard P AU - Zare Dehnavi H AU - Dastanpour Hoseinabadi M TI - Study and Comparison of the Effect of Tecar Therapy in the Symptoms and Functions of the Patients With Knee Osteoarthritis; a Non-Blind, Controlled Clinical Trial JO - Immunopathologia Persa VL - 12 IS - 2 SP - e43885 EP - PY - 2026 ER - |